[The change of intestinal mucosa barrier in chronic severe hepatitis B patients and clinical intervention].
OBJECTIVE
To study the change of intestinal mucosa barrier in chronic severe hepatitis B patients and clinical intervention.


METHODS
(1) 30 normal healthy controls and 60 chronic severe hepatitis B patients were enrolled in this study. The change of intestinal permeability was determined by urine lactulose/ mannitol ratio (L/M), and the serum diamine oxidase (DAO) was measured. (2) 60 chronic severe hepatitis B patients were randomly divided into two groups: the control group and the treated group, each group has 30 cases. Patients in the control group received standard treatment for 2 weeks, however, in addition to standard treatment, patients in the treated group also received glutamine 10g tid. Endotoxin (ET), DAO and L/M were compared between the two group.


RESULTS
(1) Compared to healthy controls, the level of L/M and DAO was significantly increased in chronic severe hepatitis B patients (t = 2.762, P less than 0.01 or t = 6.326, P less than 0.01). (2) Compared to the control group, ET, DAO and L/M were significantly lower 2 weeks after treatment (F = 11.662, P less than 0.01; F = 12.699, P less than 0.01; F = 19.981, P less than 0.01).


CONCLUSIONS
(1) There is an early intestinal mucosa barrier damage in chronic severe hepatitis B patients. (2) Compared to standard treatment, adding glutamine can reverse intestinal mucosa barrier damage.
Song
Huai-Yu
HY
Deparment of Gastroenterology, the People Hospital of Guangxi Zhuangzu Autonomous Region, Nanning 530021, China.
Jiang
Chun-Hua
CH
Yang
Jian-Rong
JR
Chen
Qiu-Hong
QH
Huang
Jun
J
Huang
Yun-Hua
YH
Liang
Lie-Xin
LX
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D006631:Amine Oxidase (Copper-Containing) / Q000097:blood; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D004731:Endotoxins / Q000097:blood; D005260:Female; D005973:Glutamine / Q000494:pharmacology / Q000627:therapeutic use*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology*; D007421:Intestine, Small; D007792:Lactulose / Q000652:urine; D008297:Male; D008353:Mannitol / Q000652:urine; D008875:Middle Aged; D010539:Permeability; D016896:Treatment Outcome; D055815:Young Adult
D000998:Antiviral Agents; D004731:Endotoxins; D005973:Glutamine; D008353:Mannitol; D007792:Lactulose; D006631:Amine Oxidase (Copper-Containing)